Variant detection and runs of homozygosity in next generation sequencing data elucidate the genetic background of Lundehund syndrome

Julia Metzger*, Sophia Pfahler and Ottmar Distl

Abstract

Background: The Lundehund is a highly specialized breed characterized by a unique flexibility of the joints and polydactyly in all four limbs. The extremely small population size and high inbreeding has promoted a high frequency of diseased dogs affected by the Lundehund syndrome (LS), a severe gastro-enteropathic disease.

Results: Comprehensive analysis of bead chip and whole-genome sequencing data for LS in the Lundehund resulted in a genome-wide association signal on CFA 34 and LS-specific runs of homozygosity (ROH) in this region. Filtering analysis for variants with predicted high or moderate effects revealed a missense mutation in LEPREL1.

In addition, ROH analysis for the Lundehund indicated a high enrichment of genes in potential signatures of selection affecting protein activation and immunoregulatory processes like NOD1 potentially involved in LS breed disposition.

Conclusions: Sequencing results for Lundehund specific traits reveal a potential causative mutation for LS in the neuropeptide operating gene LEPREL1 and suggests it as a precursor of the inflammatory process. Analyses of ROH regions give an insight into the genetic background of characteristic traits in the Lundehund that remain to be elucidated in the future.

Keywords: LEPREL1, Lundehund syndrome, Runs of homozygosity

Background

The Norwegian Lundehund represents a specific but small group in the variety of dog breeds which have evolved since domestication [1]. It stands out by exceptional characteristics like double dewclaws and extreme flexibility in shoulder and neck, which represent traits fixed in the Lundehund population [2]. In addition, the Lundehund harbors a breed disposition for a syndrome comprising particular features of protein-losing enteropathy (PLE), intestinal lymphangiectasia, gastrointestinal disturbance, inflammatory bowel disease and malabsorption designated as Lundehund syndrome (LS) [3, 4]. Clinical signs are diarrhea, vomiting, weight loss, edema and apathy often accompanied with decreased concentrations of albumin and globulin in blood profile [2]. A similar condition has been described in the Soft Coated Wheaten Terrier affecting immune system, gut and kidney [5, 6]. It was supposed that one or more genes involved in these complex systems might be responsible for a breed disposition for PLE. An increased occurrence of PLE could also be found in Rottweilers and Yorkshire terriers [7–9]. In Basenji and German Shepherd, hypoalbuminemia and hypoglobulinemia was found in dogs with severe lymphocytic-plasmacytic enteritis characterized by excessive infiltrates of mononuclear inflammatory cells [10, 11]. It was suggested
that the inflammatory bowel disease in German Shepherd was the result of a complex etiology with the involvement of different variant effects similar to Crohn’s disease, the chronic inflammatory bowel disease in human [12–15].

In the Lundehund, a signature of selection for LS was suggested to be located on CFA 9 in the region of Caspase Recruitment Domain Family, Member 9 (CARD9), which is known to be associated with Crohn’s disease and ulcerative colitis in human [16, 17]. In addition, extended haplotype homozygosity (EHH) tests suggested further breed specific characteristics like polydactyly, body size or flexibility of the joints as targets of specific selection [17]. Genotyping the limb development membrane protein 1 (LMBR1) mutation DC-2, which was shown to be associated with preaxial polydactyly in western dogs, revealed the mutant genotype (A/A) in all tested Lundehund [18, 19]. In general, the frequency of long stretches of homozygous genotypes on basis of bead chip data was shown to be high which was suggested to be a result of an extremely low genetic variability in the Lundehund breed [1, 17, 20].

In this study whole-genome sequencing was performed in two Lundehund pools comprising LS-affected and LS-unaffected individuals. Sequence data were investigated for runs of homozygosity (ROHs) and variants predicted to have high or moderate effects in order to elucidate the genetic background of LS.

Results
Phenotype

Samples of six Lundehund dogs with typical characteristics of a puffin hunter phenotype including an additional toe and joint flexibility (Fig. 1) were chosen for whole-genome sequencing in two pools. One pool enclosed three healthy dogs whereas the other pool comprised three Lundehund showing severe signs of gastroenteropathy known as LS. In addition, 12 LS-affected Lundehund with clinical signs and low blood protein parameters, 6 Lundehund suspected to be LS-affected due to recurrent diarrhea and vomiting and 12 Lundehund without clinical signs of LS classified as LS-unaffected were available for further analysis. Characteristic clinical signs were diarrhea, vomiting, weight loss and apathy (Fig. 2). The onset of first signs varied widely from the age of 2.5 to 10.5 years (Additional file 1). Some cases also showed ascites and edema in the limbs. The results of blood screening revealed hypoalbuminemia in all analyzed cases, sometimes accompanied with hypoglobulinemia, reduced levels of fructosamines and vitamin B, hypo- or hypercalcemia, as well as increased concentrations of serum folate and alanine aminotransferase.
Pedigree and association analysis

Inspection of the pedigree data of all Lundehund under study revealed close relationships among affected dogs (Additional file 2). In total 24 female and 16 male LS-affected Lundehund were included in this pedigree data. A complex segregation analysis revealed a recessive major gene model as the most likely mode of inheritance with the lowest $-2\log$-likelihood at 52.68 (Additional file 3).

Genome-wide association analysis for LS in 17 LS-affected and 8 LS-unaffected Lundehund showed a highly significant peak on CFA 34 at 26,384,304-27,498,705 bp (CanFam 2.0) corresponding to 23,373,982-24,488,983 bp in CanFam 3.1 assembly (Fig. 3) in the region of fibroblast growth factor 12 (FGF12; ENSCAFG00000031187) and mab-21 domain containing 2 (MB21D2; ENSCAFG00000014075). The highest $-\log_{10}$P value ($-\log_{10}P = 7.7$) could be shown for one SNP at 24,152,349 bp whereas further 30 SNPs in the associated region reached $-\log_{10}$P-values of 5.6-5.9. Expected versus observed $-\log_{10}$P-values (quantile-quantile-plot) showed that inflation due to stratification effects had not increased $-\log_{10}$P-values. The distribution of genotypes suggested a recessive effect as proposed by segregation analysis.

Sequencing and variant detection

Whole-genome sequencing of two Lundehund pools with three dogs each resulted in a mean coverage of 15.56X for Lundehund pool 1 (LS-affected) and 14.48X Lundehund pool 2 (LS-unaffected). In total 10,584,482 SNPs and 3,223,567 insertions/deletions (INDEL) could
be detected for pool 1 as well as 10,530,165 SNPs and 3,207,163 INDEL for pool 2 in raw data after variant calling. Stringent filters for read depth and quality of each variant led to a set of 8,815,395 SNPs (pool 1) as well as 8,799,793 SNPs (pool 2) for ROH analysis. For these SNPs the mean heterozygosity per site was 0.11 in both pools.

**LS-specific ROH detection**
A total of 1713 ROHs specific for LS-affected dogs were detected. Three ROHs could be found directly in the region of association on CFA 34 at 23,223,356-24,490,050 bp harboring the genes Coiled-Coil Domain Containing 50 (CCDC50), FGFI2 and MB21D2 (Additional file 4). In private ROHs analysis for homozygous regions which could be exclusively found in LS-affected as well as LS-unaffected Lundehund, 472 ROH regions could be detected for pool 1 (LS-affected, Additional file 5) and 408 ROH regions for pool 2 (LS-unaffected, Additional file 6). The largest private ROH region for pool 1 could also be found on CFA 15 in a wider area of 7,812,609-13,628,020 bp including 51 genes.

**Breed specific ROH**
Consensus ROH detection was performed to identify potential signatures of selection for unique breed specific characteristics whose intense human selection might be collaterally associated with the high incidence of LS in the Lundehund population.

In total 660 Lundehund specific consensuses ROH regions could be detected for 500-SNP windows (Additional file 7). A notably high number of large stretches of consecutive homozygous genotypes was found on CFA 12 in the region of 32,968,627-49,633,816 bp and CFA 7 in the region of 28,049,903-54,984,739 bp. These regions harbored a large number of genes including PRRX1 (paired related homeobox 1) and GREM2 (gremlin 2, DAN family BMP antagonist) on CFA 7. Furthermore, we detected a ROH region on CFA 14 at 42,891,687-43,618,177 bp harboring Nucleotide-Binding Oligomerization Domain Containing 1 (NOD1). In contrast, no ROH region could be detected harboring the candidate gene LMBR1 (limb development membrane protein 1) for canine polydactyl mutations [19]. Further genotyping of the intronic LMBR1 SNP DC-2 revealed the mutant DC-2 allele homozygous in all analyzed Lundehund but also in the Norwegian Buhund, Bernese Mountain Dogs, Briard and Irish Wolfhound (Additional file 8).

**Variants in ROH regions**
Detection of SNPs or INDEL predicted to have high or moderate effects in ROH regions was performed to identify LS-specific or Lundehund-specific variants. No variant with predicted high or moderate effects could be detected within FGFI2 and MB21D2 located in the region of ROHs found in the LS-affected (pool 1) which matched the region of genome-wide association. In total 2036 intron variants with a homozygous mutant genotype in LS-affected Lundehund, one 3’ UTR and 13 5’ UTR variants could be found in FGFI2 with predicted low or modifier effects only. In MB21D2 no LS-associated variant could be detected.

**Functional annotation of ROH regions**
Functional gene classification of human orthologues detected in ROH regions showed a particularly high involvement in biological processes affecting cellular processes (GO:0009987), localization (GO:0008150) and also in the perception of taste (GO:0002921) and transcription (GO:0019538, GO:0044238, GO:0019219) and transcription (GO:0006351). Private ROHs detected in LS-affected Lundehund revealed an enrichment of genes involved in cellular process (GO:0009987, GO:0006464), metabolic process (GO:0008152, GO:0019538, GO:0044238, GO:0019219) and transcription (GO:0006351). Private ROHs detected in LS-affected dogs revealed a >5 fold enrichment of genes known to play a role in negative regulation of complement activation (GO:0045916), protein activation cascade (GO:2000258), humoral immune response (GO:0002921) and also in the perception of taste (GO:0001580, GO:0005913, GO:0005912, GO:0005909). In consensus Lundehund ROH regions genes affecting single-organism (GO:004763) as well as cellular (GO:0009987) and biological (GO:0008150) processes were predicted to be overrepresented (Table 1).

**Filtering for mutations with predicted high or moderate effects**
Specific filtering for variants with predicted high or moderate effects in the region of genome-wide association for
Table 1 Statistical overrepresentation test for biological processes. All human orthologues derived from ROH detection were analyzed for an enrichment of genes involved in specific processes using PANTHER tools. The number of detected genes in ROH regions in 500-SNP windows and Gene Ontology (GO) terms are shown for Bonferroni corrected significant P-values <0.05.

| GO term                                                                 | Number of reference genes (Homo sapiens) | ROH regions in LS-affected: expected | Bonferroni corrected P-value for multiple testing | Private ROH regions in LS-affected: expected | Bonferroni corrected P-value for multiple testing | Private ROH regions in LS-unaffected: expected | Bonferroni corrected P-value for multiple testing | Lundehund consensus ROH regions: expected | Bonferroni corrected P-value for multiple testing |
|------------------------------------------------------------------------|------------------------------------------|--------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Single-organism cellular process (GO:0044763)                          | 11415                                    | ----                                 | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Single-organism process (GO:0044699)                                   | 12755                                    | ----                                 | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Cellular process (GO:0009987)                                          | 14147                                    | 1714.55                              | 3.37E-05                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Biological process (GO:0008150)                                        | 16542                                    | ----                                 | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Generation of neurons (GO:0048699)                                     | 1551                                     | ----                                 | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Neurogenesis (GO:0022008)                                             | 1628                                     | ----                                 | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Cellular component organization or biogenesis (GO:0071840)             | 5188                                     | ----                                 | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Cellular protein modification process (GO:0006464)                      | 1317                                     | 336.62                               | 1.15E-03                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Protein metabolic process (GO:0019538)                                 | 2692                                     | 688.07                               | 2.95E-04                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Metabolic process (GO:0008152)                                         | 8247                                     | 2107.91                              | 7.09E-04                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Primary metabolic process (GO:0044238)                                 | 6825                                     | 1744.45                              | 1.39E-02                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Transcription, DNA-dependent (GO:0006351)                              | 1941                                     | 496.11                               | 4.71E-03                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
| Regulation of nucleobase-containing compound metabolic process (GO:0019219) | 1700                                     | 434.52                               | 1.03E-02                                      | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          | ----                                          |
Table 2: Filtered variants from whole-genome analysis. Variants with predicted high or moderate effects and a homozygous mutant genotype exclusively found in the LS-affected pool as well as a heterozygous or homozygous wild-type genotype in the LS-unaffected pool are shown. All five reference dogs of four different breeds do not show the mutant genotype. Potential functional effects of these variants were predicted using SIFT and PolyPhen.

| CFA Position | Base change | Amino acid change | Consequence (Gene (transcript)) | Genotype (LS-affected Lunde-hund pool) | Genotype (LS-unaffected Lunde-hund pool) | Genotype (LS reference dogs) | SIFT | PolyPhen-2 |
|--------------|-------------|-----------------|---------------------------------|--------------------------------------|--------------------------------------|----------------------------|------|------------|
| 1            | 13398018    | T>G             | missense variant                | 1/1                                  | 0/0                                  |                            | tolerated (0.07) | benign (0.074)/- |
| 1            | 111903572   | A>G             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.08/ 0.13/ 0.21/ 0.2) | benign (0.00)/ benign (0.310)/ possibly damaging (0.659)/ possibly damaging (0.605)/ benign (0.250) |
| 3            | 56438357    | G>T             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.59) | benign (0.310) |
| 3            | 62265062    | A>T             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.3/ 0.31) | benign (0.023/ 0.347) |
| 5            | 16233038    | G>T             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.42/ 0.34/ 0.42) | benign (0.009/ 0.009/ 0.004) |
| 6            | 67204997    | C>T             | non coding transcript variant   | 1/1                                  | 0/1                                  |                            | tolerated (0.56) | possibly damaging (0.560) |
| 6            | 67205308    | A>C             | non coding transcript variant   | 1/1                                  | 0/1                                  |                            | tolerated (0.21) | benign (0.002) |
| 6            | 67205754    | G>A             | non coding transcript variant   | 1/1                                  | 0/1                                  |                            | tolerated (0.3/ 0.31) | benign (0.023/ 0.347) |
| 6            | 67205959    | A>G             | non coding transcript variant   | 1/1                                  | 0/1                                  |                            | tolerated (0.42/ 0.34/ 0.42) | benign (0.009/ 0.009/ 0.004) |
| 6            | 67205666    | T>G             | non coding transcript variant   | 1/1                                  | 0/1                                  |                            | tolerated (0.56) | possibly damaging (0.560) |
| 7            | 2590167     | G>A             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.21) | benign (0.002) |
| 7            | 4169250     | A>T             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.3/ 0.31) | benign (0.023/ 0.347) |
| 8            | 22616300    | C>T             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.42/ 0.34/ 0.42) | benign (0.009/ 0.009/ 0.004) |
| 8            | 47544408    | G>A             | missense variant                | 1/1                                  | 0/1                                  |                            | tolerated (0.56) | possibly damaging (0.560) |
|   | Genomic Position | Allele Change | Variant Type  | Genotype Avg. | Predicted Effect | HGVS Symbol |
|---|------------------|---------------|---------------|---------------|-----------------|-------------|
| 8 | 73685892         | C>G           | missense      | 1/1           | deleterious     | Q>H         |
| 8 | 73685923         | C>G           | missense      | 1/1           | deleterious     | W>S         |
| 8 | 73685927         | T>G           | missense      | 1/1           | tolerated       | S>R         |
| 9 | 37739213         | C>T           | missense      | 1/1           | deleterious     | R>W         |
| 9 | 51227945         | T>C           | missense      | 1/1           | deleterious     | H>R         |
| 10| 36330685         | C>T           | missense      | 1/1           | tolerated       | A>V         |
| 11| 67454670         | A>C           | missense      | 1/1           | tolerated       | S>R         |
| 12| 4030108-4030109  | A>AGG         | frameshift    | 1/1           | -               | R47fs       |
| 12| 52354031         | A>G           | missense      | 1/1           | deleterious     | F>S         |
| 12| 52354041         | G>A           | missense      | 1/1           | deleterious     | L>F         |
| 14| 16187782         | T>G           | missense      | 1/1           | tolerated       | I>M         |
| 14| 22993351         | A>T           | missense      | 1/1           | tolerated       | C>S         |
| 18| 39577830         | C>T           | missense      | 1/1           | tolerated       | A>V         |
| 20| 54722514         | T>C           | missense      | 1/1           | tolerated       | I>M         |
| 27| 2322565          | C>T           | missense      | 1/1           | deleterious     | R>C         |
| 28| 31706107         | A>C           | missense      | 1/1           | tolerated       | N>T         |
| 32| 21555092         | C>T           | missense      | 1/1           | tolerated       | D>N         |
| 34| 22046092         | C>G           | missense      | 1/1           | tolerated       | E>Q         |
| X | 96702059         | A>G           | missense      | 1/1           | tolerated       | R>G         |

* is the official HGVS-symbol for a stop codon
LS revealed no variant directly in this region but one missense mutation 1.2 Mb proximal to the peak of association in the candidate gene LEPREL1 (Table 2). It was predicted to result in a substitution glutamic acid to glutamine.

In addition, specific filtering was done for further candidate variants which could potentially be involved in disease development of LS and might have been missed in the specified ROH detection windows or association analysis. We extracted genetic variants putatively associated with LS with predicted high or moderate effects which showed a homozygous mutant genotype only in LS-affected and a heterozygous mutant or wildtype genotype in LS-unaffected dogs. In total 32 SNPs and one INDEL resulted from filtering analysis.

Based on these results we chose the missense mutation LEPREL1:g.139212C>G near the region of genome-wide association and further six single nucleotide variants (SNV) in other genomic regions which were predicted to be deleterious (SIFT [21]) as well as possibly or probably damaging (PolyPhen [22]) for validation in all Lundehund samples and across several dog breeds. Three of these SNVs located in regions of an extreme high density of mutations, probably a result of inaccurate gene annotation, were assumed to be false positive results and therefore omitted from analysis. Genotyping of the remaining four non-synonymous SNVs in the region of the candidate genes leprecan-like 1 (LEPREL1), centrosomal protein 164 kDa (CEP164), collagen, type XXVII, alpha 1 (COL28A1) and keratin 3 (KRT3) in 36 Lundehund revealed a significant association of CEP164:g.57380G>T and LEPREL1:g.139212C>G with LS (Table 3).

Further genotyping of 186 dogs of 17 breeds with no signs of gastroenteropathic disease showed only LEPREL1:g.139212C>G and COL28A1:g.159951T>A to be breed specific mutations for the Lundehund (Additional file 10) and revealed no significant P-value for COL28A1:g.159951T>A, but a significant P-value of 1.503E-29 for LEPREL1:g.139212C>G (Table 4). A closer look at the LS-phenotypes showed that all 17 LS-affected Lundhund harbored the homozygous mutant LEPREL1:g.139212C>G genotype whereas three of the six dogs which were estimated to be LS-suspicious due to clinical signs, did not show the homozygous mutant genotype.

**Candidate gene sequencing**

Sequence analysis of LEPREL1 cDNA confirmed the missense mutation in exon 13 in LS-affected Lundehund dogs. No further SNVs could be found in LEPREL1 to be associated with LS (Additional file 11). Sequencing the complementary DNA (cDNA) of MB21D2 in an affected Lundehund and a reference German Shepherd dog revealed three mutations. Nevertheless, none of these mutations could be exclusively found in the Lundehund. The predicted gene FGF12 cDNA could not be amplified at all.

**Table 3** Genotypic distribution of candidate SNPs for LS in Lundehund dogs. Chi-square test results are shown for the four candidate SNPs chosen from filtering analysis for mutations predicted to have high or moderate effects. Genotypes are assigned to Lundehund without signs of LS (0), LS-affected Lundehund (1) and LS-suspicious dogs (1 susp.) due to clinical signs.

| CFA | Gene     | Polymorphism | CFA Gene Polymorphism | LS status (affected (1) or unaffected (0)) | Genotype 0/0 (number and frequency) | Genotype 0/1 (number and frequency) | Genotype 1/1 (number and frequency) |
|-----|----------|--------------|------------------------|------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| 34  | LEPREL1  | LEPREL1:g.139212C>G | 6.807 (P = 0.033)     | 4.959 (P = 0.026)                     | 4.293 (P = 0.038)           | 0                                   | 1 (2.78)                          | 7 (19.44)                          | 7 (19.44)                          |
|     |          |              |                        |                                          | 1 (0.00)                           | 0 (0.00)                           | 15 (41.70)                         |                                    |
|     |          |              |                        |                                          | 1 (susp.)                          | 2 (5.56)                           | 3 (8.34)                           |                                    |
| 5   | CEP164   | CEP164:g.57380G>T | 6.264 (P = 0.044)     | 4.538 (P = 0.033)                     | 4.412 (P = 0.036)           | 0                                   | 4 (11.43)                          | 6 (17.14)                          | 5 (14.29)                          |
|     |          |              |                        |                                          | 1 (0.00)                           | 7 (19.46)                          | 7 (19.46)                          |                                    |
|     |          |              |                        |                                          | 1 (susp.)                          | 2 (5.56)                           | 4 (11.12)                          |                                    |
| 14  | COL28A1  | COL28A1:g.159951T>A | 0.614 (P = 0.736)     | 0.019 (P = 0.889)                     | 0.021 (P = 0.883)           | 0                                   | 3 (8.57)                          | 7 (20.00)                          | 5 (14.29)                          |
|     |          |              |                        |                                          | 1 (susp.)                          | 2 (5.72)                           | 8 (22.80)                          | 4 (11.44)                          |
|     |          |              |                        |                                          | 1 (susp.)                          | 1 (2.86)                           | 4 (11.44)                          | 1 (2.86)                           |
| 27  | KRT3     | KRT3:g.2584C>T   | 3.379 (P = 0.184)     | 2.483 (P = 0.115)                     | 2.146 (P = 0.143)           | 0                                   | 3 (8.33)                          | 8 (22.22)                          | 4 (11.11)                          |
|     |          |              |                        |                                          | 1                                  | 3 (8.33)                           | 4 (11.12)                          | 8 (22.22)                          |
|     |          |              |                        |                                          | 1 (susp.)                          | 0 (0.00)                           | 2 (5.56)                           | 4 (11.12)                          |
Table 4 Chi-square test for Lundehund dogs and seventeen different breeds. Other breeds are used as controls for Lundehund-specific LS. The test results are shown for the four candidate SNPs chosen from filtering analysis for mutations predicted to have high or moderate effects.

| CFA | Gene   | Polymorphism       | Chi-Square genotype (Probability) | Chi-Square allele (Probability) | Chi-Square trend (Probability) |
|-----|--------|--------------------|-----------------------------------|-------------------------------|--------------------------------|
| 34  | LEPRE1 | LEPRE1:g.139212C>G  | 132.735 (P = 1.503E-29)            | 238.686 (P = 7.607E-54)       | 130.861 (P = 2.655E-30)       |
| 5   | CEP164 | CEP164:g.57380G>T   | 83.884 (P = 6.092E-19)             | 120.165 (P = 5.822E-28)       | 83.716 (P = 5.712E-20)        |
| 14  | COL28A1| COL28A1:g.159591T>A | 101.034 (P = 1.150E-22)           | 116.566 (P = 3.573E-27)       | 79.531 (P = 4.748E-19)        |
| 27  | KRT3   | KRT3:g.2584C>T      | 3.379 (P = 0.184)                 | 2.483 (P = 0.115)             | 2.146 (P = 0.173)            |

Discussion

Whole-genome sequencing analysis in two pools of Lundehund dogs revealed a candidate gene for LS-disposition and gave evidence for potential LS-related signatures of selection. The genome-wide association analysis resulted in a significant peak on CFA 34 which could also be shown to be located in a ROH region for LS-affected dogs. Screening of whole-genome data did not reveal any LS-associated mutations with predicted high impacts on protein function but the missense mutation LEPRE1:g.139212C>G 1.2 Mb proximal of the region of significant genome-wide association. We assume that the shift of the peak of LS-association and LS-associated ROH region might be a result of the low bead chip marker density that could be found in the region of LEPRE1. Furthermore, it could be shown that the detection of ROHs is strongly dependent on the window size and marker density [23] so that not all homozgyous stretches can be detected in 500-SNP windows.

We assume that smaller windows could probably have enabled the detection of a ROH region comprising LEPRE1 but might have increased the number of false positive results, too. According to the suggested recessive mode of inheritance the missense mutation LEPRE1:g.139212C>G could be shown to be homозygos in all analyzed dogs in NGS data. LS-affected dogs showed the mutant genotype G/G whereas LS-unaffected controls of other breeds did harbor the homozgyous wild type C/C. In addition, seven Lundehund with no clinical signs for LS also showed the mutant genotype G/G. Due to the variable onset of the disease it can be proposed that these dogs will develop signs of the disease later in their life. We suggest this SNV as a potential causative mutation for a genetic disposition for LS.

LEPRE1 was shown to be expressed in a subpopulation of neuroendocrine cells of the intestinal mucosa and suggested to be important for processing and secretion of neuropeptides [24]. It was proposed that the enteric nervous system could trigger the occurrence of inflammatory bowel disease through neuropeptide secretion [25]. Neuropeptides were proposed to play a key role in inflammatory bowel diseases [25, 26]. Blockades for these molecules were considered for therapeutic approaches. We assume mutant LEPRE1 might be an essential precursor for LS in the Lundehund. Lundehund without clinical signs for LS who harbor this mutant RNA could possibly be subclinically affected or fall ill later in their life by specific trigger mechanisms. It was shown that not a few Lundehund who appeared healthy often had abnormal findings in histopathologic examinations [2]. The onset of the disease could be influenced by external factors triggering phenotypic expression. In the Soft Coated Wheaten Terrier it was proposed that food allergies could play a role in the development of PLE [5, 27]. In addition to external factors, further genes might be involved in triggering LS as well as influence the severity of symptoms. In human Crohn’s disease various mutations have been shown to be associated with disease development in different populations [13, 28–33]. It was suggested that complex regulatory processes driven by various genes could affect the extent of defects and result in different severities.

We assume that further genes might be involved in LS-development and could potentially be related to targets of selection for breed specific traits. This could probably explain the high incidence of LS in the population. In general, ROH analysis for the Lundehund showed a high frequency of long stretches of homozgyous genotypes as expected from the extremely low genetic variability of this breed [1]. A high enrichment of genes in these ROH regions affecting protein activation, complement activation and humoral immune response suggested that protein-protein interactions and immunoregulatory processes might play an important role in the development of LS in the Lundehund as it was previously proposed for PLE in the Soft Coated Wheaten Terrier [5].

Variants in the candidate gene NOD1 (CARD4), which could be found to harbor a Lundehund specific ROH region, have been shown to be highly susceptible to inflammatory bowel disease [30]. It was proposed that NOD1 plays an important role in colonic epithelial protection against intracellular organisms similar to mucin genes. In Lundehund affected with atrophic gastritis an abnormal presence of mucous neck cells could be
detected in the gastric mucosa [34]. We suppose that this gene, potentially under targeted selection in the Lundehund, might predispose this breed in general for gastrointestinal problems.

Further potential signatures of selection could be detected in the region of genes that might be involved in breed specific conformational traits like joint flexibility or polydactyly. According to Lundehund breed standard, the Lundehund was reported to have at least six toes at fore and hind limps [2, 18, 20]. Mapping analysis for hind limp specific canine preaxial polydactyly revealed a potentially causative mutation in LMBRI (DC-2) in western dog breeds [19]. The homozygous mutant DC-2 genotype was also found in the Lundehund [18] and could be confirmed in all 36 Lundehund in our study. Nevertheless, it was still unclear if this mutation could explain the characteristic phenotype in the Lundehund showing polydactyly at both fore and hind limps in contrast to the usually unchanged forelimb in dogs with polydactyly [19]. We found evidence in Lundehund consensus ROH regions for potential modifier genes that might play a role in limb development. GREM2 was shown to be expressed in osteoblasts during in vivo skeletogenesis and involved in the regulation of bone formation genes [35, 36]. It was suggested that GREM2 was bidirectionally regulated by bone morphogenetic protein 2 (BMP2) together with GREM1, a gene which was shown to be expressed along with sonic hedgehog (SHH) and play an important role in limb bud development [36, 37]. A similar effect was suggested for PRRX1 (PRX1). Loss-of-function mutant PRRX1/PRRX2 mice resulted in shortened zeugopods of the forelimbs and hindlimbs as well as postaxial polydactyly in the forelimb [38]. EHH analysis in the Lundehund revealed PRRX2 in long-range homozygous haplotypes suggesting this gene as a candidate for Lundehund-polydactyly [17]. We assume that these genes under potential targeted selection could explain the specific phenotypic characteristic for a four-limb polydactyly in the Lundehund.

Conclusions
In conclusion, our study of whole-genome sequencing data of Lundehund dogs suggests LEPREL1:g.139212C>G as a potential causative mutation for LS as well as NOD1 as a potential precursor gene which might play a role in LS breed predisposition. In addition, we identified potential signatures of selection for characteristic breed specific traits whose targeted selection might have increased genetic risk factors for disease development.

The results of our analysis represent a significant step to identify the genetic background of Lundehund specific traits which still remain to be further investigated for proper understanding of the underlying complex genetic mechanisms.

Methods
Animals
Genomic DNA was obtained from blood samples of 36 Lundehund and 186 dogs of different dog breeds including Norwegian Buhund and Norrbottenspets using a standard saline precipitation method [39]. Lundehund specific phenotypes and affection-status were obtained on basis a questionnaire filled in by dog owners and veterinarians. Information about the pedigree, date of birth, date of euthanasia and signs of LS like diarrhea, vomiting and cachexia was recorded using this form. Further blood parameters were added from clinically examined dogs.

Association analysis
In total 25 Lundehund (17 LS-affected and 8 LS-unaffected) were genotyped on the canine Illumina high density bead chip (Illumina) according to manufacturer’s protocols. Quality of genotyping data was controlled using a minor allele frequency (MAF) >0.05 and a genotyping rate per SNP >0.90. Filtering resulted in 93,882 SNPs with a mean genotyping rate of 99 %. Genomewide association analysis was run using TASSEL version 3.0 [40]. Generalized linear model (GLM) with sex, inbreeding coefficients and three PCA’s was run to test the model. Quantile-quantile (Q-Q) plots for observed versus expected -log10P-values were calculated to control for population stratification using SAS/Genetics.

Pedigree analysis
Pedigree analysis was performed using regressive logistic models and the procedure SEGREG of S.A.G.E. (Statistical Analysis for Genetic Epidemiology, Release 6.3: http://darwin.cwru.edu, 2012) to test the most likely mode of inheritance for LS. We tested the hypothesis for the μ model without any genetic component, monogenic inheritance, polygenic inheritance and mixed major gene inheritance with a polygenic component and an independently segregating major gene locus with two alleles.

Whole-genome sequencing
Whole genome sequencing of Lundehund samples was performed on the Illumina MiSeq (Illumina, San Diego, CA) in paired-end mode. Libraries were prepared for one DNA-pool of three LS-affected Lundehund and for one DNA-pool of three LS-unaffected Lundehund using the Illumina Nextera DNA Sample Prep Kit according to standard protocols. We performed four runs for each pool with v2 Reagent Kits (Illumina) on a single lane flow cell (2 × 250 bp reads). Fastq-files were quality controlled using fastqc 0.11.3 [41]. Mapping to the reference genome CanFam 3.1.78 was performed using BWA 0.7.12 [42] followed by conversion into binary format using SAMtools 1.2 [43] and PCR duplicate marking
using Picard tools (http://broadinstitute.github.io/picard/, version 1.130). Furthermore, we locally realigned reads and performed quality score recalibration and SNP calling using GATK [44]. In addition to the Lundehund fastq files we added five whole-genome sequences of one Korean Jindo Dog (DRR001566), one Afghan Hound (SRRI061643), two German Shepherd dogs (SRRI130247 and SRRI124304) and one Border Collie (SR8654728) from Sequence Read Archive (NCBI) to analysis. Quality of the data was controlled filtering variants for a read depth >2 and <1000 and quality values >20 (qual). Variant effects were predicted using the genetic variant annotation and effect prediction toolbox SNPEff version 4.1 b (2015-02-13) [45].

ROH detection
ROHs were detected using a stringently quality-controlled autosomal dataset of 8,585,517 SNPs showing a minimum read depth of 3, a maximum read depth of 60, a minimum mean read depth of 12 and minor allele frequency 0.01 for all samples. Sliding windows of 500 SNPs were chosen for ROH analysis. Homozygous regions of >150 kb were detected as ROHs using PLINK, version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). Based on the genome size covered with SNPs divided by the number of SNPs we estimated the minimum distance of SNPs as 0.3. A maximum of three SNPs with missing genotypes and three heterozygous SNPs were admitted in each window. ROHs were filtered for LS-specific and Lundehund specific ROH regions based on hom.summary data outputs from ROH analysis for each dog using SAS/Genetics, version 9.4 (Statistical Analysis System, Cary, NC). The homozygosity information of each SNP (1 = homozygosity, 0 = no homozygosity) was detected and compared to the other individuals in order to identify overlapping and private regions, the number of SNPs and length of the regions. These specific ROH regions were searched for variants predicted to have high or moderate effects (SNPEff).

Functional annotation
Chromosomal positions of ROH regions were merged with Ensembl gene predictions (ensGene) using Galaxy intersection tool (https://usegalaxy.org/) [46, 47]. The obtained gene lists were converted into human orthologous genes using gProfiler [48, 49] and tested for statistical overrepresentation in biological processes (PANTHER Overrepresentation Test; release 20150430, version 10.0) [50].

Filtering analysis
Analysis of sequencing data was performed identifying variants with SNPEff-predicted high or moderate effects with a homozygous mutant genotype in the LS-affected pool, a heterozygous or homozygous wild-type genotype in LS-unaffected pool and a homozygous wild-type genotype in the other five dogs of different breeds using SAS/Genetics 9.4. Variants flagged with warnings about possible annotation accuracy problems were omitted from analysis. The candidate SNP in LEPRELI and further 23 SNPs were investigated for functional effects using the Variant Effect Predictor [51] for SIFT [21] predictions and PolyPhen [22]. Regions of SNPs that were predicted to be deleterious (SIFT) and possibly or probably damaging (PolyPhen) had been further investigated for a high density of mutations around the candidate SNP that could reference to annotation problems.

Genotyping
Genotyping of the candidate SNPs LEPRELI:g.139212C>G, KRT3: g.2584C>T as well as the polydactyly-associated polymorphism in LMBRI (DC-2) was performed using restriction fragment length polymorphisms according to standard protocols [52]. DC-2 primers were obtained from previous study [18]. In addition the missense variants CEP164:g.57380G>T and COL28A1:g.159951T>A were validated using Kompetitive Allele Specific PCR (KASP) genotyping assays (LGPC, Waltham, Massachusetts, USA). After the KASP standard thermal cycling touchdown protocol was run on a thermocycler TProfessional 96 (Biometra, Göttingen, Germany) using an annealing temperature of 61 °C (Additional file 12), allelic discrimination was performed on the ABI7300 sequence detection system (Applied Biosystems, Waltham, Massachusetts, USA).

Sequencing of candidate genes
Sanger sequencing of the cDNA of MB21D2 and LEPRELI was performed in one LS-affected Lundehund and one Great Dane as control dog. RNA was obtained from hair roots in stabilized RANALater reagent (Quiagen, Maryland, USA), transcribed into cDNA and used for PCR amplification according to a standardized protocol [54] (Additional file 13). Alignment and variant detection was performed using the analysis software Sequencher 4.8 (Genes Codes, Ann Arbor, MI, USA). Despite the use of Q-solution (Quaigen) as enhancer reagent and Gradient PCR for optimizing reaction conditions, the coding region of FGF12 could not be amplified from these hair root samples at all.

Additional files

**Additional file 1:** Clinical data of 21 Lundehund with signs of LS. Blood parameters of total protein (TP), albumin (ALB), globulin (GLOB), fructosamine (F), alkaline phosphatase (ALKP), alanine aminotransferase (ALT), vitamin B12 (B12) and folic acid (FA) are shown. (DOCX 18 kb)

**Additional file 2:** Pedigree of LS-affected Lundehund. In total, samples of twenty-one LS-affected and fifteen LS-unaffected Lundehund were available for analysis. A common pedigree for all these dogs shows a close relationship in-between all Lundehund dogs. Whole genome
Additional file 3: Results of complex segregation analysis using regressive logistic models for LS in the Lundehund. (DOCX 12 kb)

Additional file 4: Runs of homozygosity for LS-affected Lundehund in 500-SNP windows. The chromosomal position of ROH regions, number of SNPs in these regions (n), size in base pairs (size_bp), canine genes (gene) and human orthologues (human gene) are shown. (XLSX 60 kb)

Additional file 5: Private runs of homozygosity for LS-affected Lundehund in 500-SNP windows. The chromosomal position of ROH regions, number of SNPs in these regions (n), size in base pairs (size_bp), canine genes (gene) and human orthologues (human gene) are shown. (XLSX 65 kb)

Additional file 6: Private runs of homozygosity for LS-affected Lundehund in 500-SNP windows. The chromosomal position of ROH regions, number of SNPs in these regions (n), size in base pairs (size_bp), canine genes (gene) and human orthologues (human gene) are shown. (XLSX 66 kb)

Additional file 7: Runs of homozygosity for Lundehund specific regions in 500-SNP windows. The chromosomal position of ROH regions, number of SNPs in these regions (n), size in base pairs (size_bp), canine genes (gene) and human orthologues (human gene) are shown. (XLSX 88 kb)

Additional file 8: Genotyping results for DC-2 mutation. The intronic LMBR1 SNP which is known to be associated with polydactyly (Park, 2008) was genotyped for all Lundehund and further 13 different dog breeds. (DOCX 13 kb)

Additional file 9: Functional annotations for runs of homozygosity (ROH) in the Lundehund. PANTHER gene list analysis shows the proportion of gene hits against total number of process hits for genes detected in Lundehund consensus as well as LS-specific and private ROHs for LS-affected and LS-unaffected dogs. Detected ROHs were investigated for genes and their involvement in specific biologic processes. (DOCX 16 kb)

Additional file 10: Allele frequencies of candidate SNPs. In total 186 samples of 17 breeds were genotyped for the LS-candidate SNPs LEPREL1:g.139212C>G, KRT3g.2584C>T, COL28A1:g.159951T>A and CEP164:g.57380G>T. In KRT3g.2584C>T and CEP164:g.57380G>T the mutant allele could be detected in other breeds whereas LEPREL1:g.139212C>G and COL28A1:g.159951T>A could not be found in any other dog breed than the Lundehund. (DOCX 14 kb)

Additional file 11: Mutations detected in sequencing analysis of M2B1D2 and LEPREL1. None of the synonymous as well as 3 prime UTR mutations could be shown to be exclusively found in the Lundehund except LEPREL1:c.1849C>G. (DOCX 13 kb)

Additional file 12: Primer sequences used for genotyping of candidate SNPs. The two variants located in KRT3 and LEPREL1 were genotyped by the use of restriction fragment length polymorphisms (RFLP). KASP-primers were used for genotyping CEP164 and COL28A1 variants. Primer pairs, amplicon size (AS) in base pairs (bp), annealing (AT), restriction enzyme and incubation temperature (IT) are shown. The polymorphism DC-2 in LMBR1 was detected using primer pairs previously published (Kropatsch, 2015). (DOCX 14 kb)

Additional file 13: Sequences of primers used for the investigation of M2B1D2 and LEPREL1 complementary DNA. The gene region, product sizes in base pairs (bp) and annealing temperatures are shown. (DOCX 13 kb)

Abbreviations

CARD9, Caspase Recruitment Domain Family, Member 9; CCDC50, Coiled-Coil Domain Containing 50; cDNA, complementary DNA; CEP164, centrosomal protein 164 KDa; COL28A1, collagen, type XXVII, alpha 1; EHH, extended haplotype homozygosity; FGF21, fibroblast growth factor 12; GLM, generalized linear model; GREM2, gremlin 2, 2 DAN family BMP antagonist; GWAS, genome-wide association analysis; KRT3, keratin 3; LEPREL1, leprecan-like 1; LMBR1, limb development membrane protein 1; LS, Lundehund syndrome; M2B1D2, mb-21 domain containing 2; NOD1, Nucleotide-Binding Oligomerization Domain Containing 1; PLE, protein-losing enteropathy; PRRX1, paired related homeobox 1; ROH, runs of homozygosity; SHH, sonic hedgehog; SNV, single nucleotide variant

Acknowledgements

The authors thank all dog owners and veterinarians for their support and for their donation of data. We also thank J. Weide for his help in data analysis and M. Drabert for his support in DNA isolation.

Funding

No funding was obtained for this study.

Availability of data and material

All fastq files analysis can be obtained by NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra), BioProject PRJNA309755 (SRX1546460, SRX1546461).

Authors’ contributions

JM, OD designed the study, carried out the experiments and data analysis, drafted and finalized the manuscript. SP performed data collection and sample preparation for bead chip analysis. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the dog owners to use their samples from the bio-bank for Lundehund research and in addition to use individual images from their dogs for further investigations and publication.

Ethics approval and consent to participate

All animal work has been conducted according to the national and international guidelines for animal welfare. EDTA-blood samples were derived from the bio-bank for diagnostic purposes and did therefore not require an animal welfare committee approval according to the German Animal Welfare Law.

Received: 29 January 2016 Accepted: 17 June 2016

Published online: 02 August 2016

References

1. Melis C, Borg AA, Espelien IS, Jensen H. Low neutral genetic variability in a specialist puffin hunter: the Norwegian Lundehund. Anim Genet. 2013;44(3):348–51.
2. Berghoff N, Ruaux CG, Steiner JM, Williams DA. Gastroenteropathy in Lundehunds. America. 2007;14–7.
3. Fleśprüf, Yr T. Protein-losing enteropathy in the Lundehund. J Small Anim Pract. 1977;18(1):11–23.
4. Kolbjørnsen Ø, Press CM, Landsverk T. Gastroenteritis of Basenji dogs. Veterinary Pathology Online.
5. Rottweilers. Tijdschr Diergeneeskd. 2010;135(10):406–8.
6. Bassetts (1992–1998). J Am Vet Med Assoc. 2000;217(5):703–6.
7. Kimmel SE, Waddell LS, Michel KE. Hypomagnesemia and hypocalcemia associated with protein-losing enteropathy in Yorkshire terriers: five cases (1992–1998). J Am Vet Med Assoc. 2002;217(5):703–6.
8. Jacobs G, Collins-Kelly L, Lappin M, Tyler D. Lymphocytic-plasmacytic enteritis in 24 dogs. J Vet Intern Med. 1990;4(2):45–53.
12. Kathrani A, Lee H, White C, Catchpole B, Murphy A, German A, Werling D, Allenpack K. Association between nucleotide oligomerisation domain two (NOD2) gene polymorphisms and canine inflammatory bowel disease. Vet Immunol Immunopathol. 2014;161(1–2):32–41.

13. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tyk C, O’Morain CA, Gassull M. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599–603.

14. Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann’s disease). Orphanet J Rare Dis. 2008;3(51):b1.

15. Solid LM, Mårkussen G, Ek J, Gjerde H, Vandal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 1989;169(1):345–50.

16. Zhemakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monsuur AJ, Bevova M, Nijmeijer RM, van ’t Slot R, Heijmans R, Boezen HM, van Heel DA, van Bodegraven AA, Stokkers PC, Wijmenga C, Crusius JB, Weersma RK. Genetic analysis of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008;82(2):1202–10.

17. Pfäfler S, Distl O. Effective population size, extended linkage disequilibrium and signatures of selection in the rare dog breed Lundehund. PLoS One. 2015;10(4):e0122680.

18. Klopatsch R, Mels C, Cronen AV, Jensen H, Eiplen JT. Molecular Genetics of Sex Identification, Breed Ancestry and Polydactyly in the Norwegian Lundehund Breed. J Hered. 2015;106:403–406.

19. Pfäfler S, Park K, Kang J, Subedi KP, Ha IJ, Park C. Canine polydactyl mutations with heterogenous origin in the conserved intrinsic sequence of LMBR1. Genetics. 2008;179A(9A):1623–72.

20. Pfäfler S, Distl O. A massive reduction of the genetic diversity in the great Danes with ichthyosis. Plos One. 2015;10(4):e0122680.

21. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–81.

22. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.

23. Metzger J, Kanwath M, Tonda R, Beltran S, Agueda L, Gut M, Gut IG, Distl O. Runs of homozygosity reveal signatures of positive selection for reproduction traits in breed and non-breed horses. BMC Genomics. 2015;16(1):764.

24. Jäumus S, Kellman C, Darabi A, Nilsson I, Edvardsen K, Årman P. LEPREL1, a novel ER and Golgi resident member of the Leprecan family. Biochem Biophys Res Commun. 2004;317(2):342–51.

25. Gross KJ, Pothoulakis C. Role of neutrophilic inflammasome in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(7):918–32.

26. Yamamoto H, Morise K, Kusugami K, Furusawa A, Konagaya T, Nishio Y, Hirayama T, Chiba Y, Nishikawa Y, Matsumoto S, Watanabe T. Identification of genetic polymorphisms in TLR2 and TLR4 and their association with Crohn’s disease. J Hum Genet. 2005;50(5):257–60.

27. Zeller R, Zuniga A, Shh and Gremlin1 chromosomal landscapes in development and disease. Curr Opin Genet Dev. 2007;17(5):628–38.

28. ten Berge D, Brouwer A, Konving J, Martin JF, Meijlink F, Buckler ES. TASSEL: software for association mapping of complex traits in diverse samples. Bioinformatics. 2007;23(19):2633–5.

29. Andrews S. FastQC: A quality control tool for high throughput sequence data. In: Reference Source. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.

30. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(1):539–46.

31. Bradbury PJ, Zhang Z, Kroon DE, Casstevens TM, Ramdoss Y, Buckler ES. TASSEL: software for association mapping of complex traits in diverse samples. Bioinformatics. 2009;25(16):2073–9.

32. Metzger J, Schrimpf R, Philipp U, Distl O. Expression Levels of LCORL Are Regulated By loss of BMP function, during osteoblast differentiation. Curr Protoc Mol Biol. 2010;89:19. 10. 11

33. Nekrutenko A, Taylor J. Galaxy: a web-based genome analysis tool for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 2010;11(8):R86.

34. Metzger J, Schrimpf R, Philipp U, Distl O. Expression Levels of LCORL Are Regulated By loss of BMP function, during osteoblast differentiation. Curr Protoc Mol Biol. 2010;89(1):88.

35. Ideno H, Takanabe R, Shimada A, Imaizumi K, Araki R, Abe M, Nifuji A. Identification of the MBSF1 gene, a novel SLC27A4 splice acceptor site mutation in Melgarejo LT, VanCamp SD, Williams DA. Food hypersensitivity reactions in children: a comparison between children with atopy and without atopy. PLoS One. 2015;10(10):e0141514.

36. Abo-Pdf I, Laas M, Yi C, Zhao X, Naim HY, Distl O. A Novel SLC27A4 splice acceptor site mutation in great Danes with ichthyosis. Plos One. 2015;10(10):e0141514.